5-MeO-MET

Nowadays, 5-MeO-MET is a topic on everyone's lips. Whether due to its historical relevance, its impact on society or its influence in today's world, 5-MeO-MET has become a point of interest for researchers, academics and the general public. In this article, we will explore this topic in depth from different perspectives, analyzing its origins, evolution and consequences in different areas. Furthermore, we will try to provide a complete and detailed overview of 5-MeO-MET, addressing both its positive and negative aspects. Without a doubt, 5-MeO-MET is a fascinating topic that arouses the curiosity of many, and we are sure that the information we will present here will be of great interest to our readers.

5-MeO-MET
Identifiers
  • N-Ethyl-2-(5-methoxy-1H-indol-3-yl)-N-methylethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20N2O
Molar mass232.327 g·mol−1
3D model (JSmol)
  • CCN(CCc1cc2c1cc(OC)cc2)C
  • InChI=1S/C14H20N2O/c1-4-16(2)8-7-11-10-15-14-6-5-12(17-3)9-13(11)14/h5-6,9-10,15H,4,7-8H2,1-3H3
  • Key:AVECDEWGCOLCPZ-UHFFFAOYSA-N

5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) is a relatively rare designer drug from the substituted tryptamine family, related to compounds such as N-methyl-N-ethyltryptamine and 5-MeO-DMT.[1][2][3] It was first synthesised in the 1960s and was studied to a limited extent,[4][5] but was first identified on the illicit market in June 2012 in Sweden.[6] It was made illegal in Norway in 2013,[7] and is controlled under analogue provisions in numerous other jurisdictions.

See also

References

  1. ^ Schifano F, Orsolini L, Papanti D, Corkery J (2017). "NPS: Medical Consequences Associated with Their Intake". Current Topics in Behavioral Neurosciences. 32: 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. PMID 27272067.
  2. ^ Palma-Conesa ÁJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M (2017). "Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis". Journal of Psychoactive Drugs. 49 (4): 297–305. doi:10.1080/02791072.2017.1320732. PMID 28569652. S2CID 45394561.
  3. ^ Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA (December 2020). "Toxicology and Analysis of Psychoactive Tryptamines". International Journal of Molecular Sciences. 21 (23): 9279. doi:10.3390/ijms21239279. PMC 7730282. PMID 33291798.
  4. ^ Gessner PK, Godse DD, Krull AH, McMullan JM (March 1968). "Structure-activity relationships among 5-methoxy-n:n-dimethyltryptamine, 4-hydroxy-n:n-dimethyltryptamine (psilocin) and other substituted tryptamines". Life Sciences. 7 (5): 267–77. doi:10.1016/0024-3205(68)90200-2. PMID 5641719.
  5. ^ Glennon RA, Gessner PK (April 1979). "Serotonin receptor binding affinities of tryptamine analogues". Journal of Medicinal Chemistry. 22 (4): 428–32. doi:10.1021/jm00190a014. PMID 430481.
  6. ^ "EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). New drugs in Europe, 2012.
  7. ^ "Forskrift om endring i forskrift om narkotika" [Regulations amending the regulations on drugs]. Lovdata (in Norwegian).